Chemistry: molecular biology and microbiology – Vector – per se
Reissue Patent
2011-05-17
2011-05-17
Schultz, James (Doug) (Department: 1633)
Chemistry: molecular biology and microbiology
Vector, per se
C435S069100, C435S325000, C424S093100, C424S191100, C536S023100
Reissue Patent
active
RE042373
ABSTRACT:
The present invention provides adenoviral vectors comprising cell status-specific transcriptional regulatory elements which confer cell status-specific transcriptional regulation on an adenoviral gene. A “cell status” is generally a reversible physiological and/or environmental state. The invention further provides compositions and host cells comprising the vectors, as well as methods of using the vectors.
REFERENCES:
patent: 5648478 (1997-07-01), Henderson
patent: 5698443 (1997-12-01), Henderson et al.
patent: 5834306 (1998-11-01), Webster et al.
patent: 5871726 (1999-02-01), Henderson et al.
patent: 5998205 (1999-12-01), Hallenbeck et al.
patent: 6495130 (2002-12-01), Henderson et al.
patent: 6991935 (2006-01-01), Henderson et al.
patent: 7575919 (2009-08-01), Yu et al.
patent: 2003/0095989 (2003-05-01), Irving et al.
patent: 0845537 (1998-06-01), None
patent: 0845537 (1998-06-01), None
patent: WO 98/39466 (1998-09-01), None
patent: WO 98/39466 (1998-09-01), None
patent: WO 95/11984 (1995-05-01), None
patent: WO 95/11984 (1995-05-01), None
patent: WO 95/14100 (1995-05-01), None
patent: WO 95/14100 (1995-05-01), None
patent: WO 95/14100 (1995-05-01), None
patent: WO 96/17053 (1996-06-01), None
patent: WO 96/17053 (1996-06-01), None
patent: WO 96/34969 (1996-11-01), None
patent: WO 96/34969 (1996-11-01), None
patent: WO 96/34969 (1996-11-01), None
patent: WO 97/01358 (1997-01-01), None
patent: WO-97/01358 (1997-01-01), None
patent: WO 98/06864 (1998-02-01), None
patent: WO 98/06864 (1998-02-01), None
patent: WO 98/06864 (1998-02-01), None
patent: WO 98/13508 (1998-04-01), None
patent: WO 98/13508 (1998-04-01), None
patent: WO 98/35028 (1998-08-01), None
patent: WO 98/35028 (1998-08-01), None
patent: WO 98/35028 (1998-08-01), None
patent: WO 98/39466 (1998-09-01), None
Abe et al., “Characterization of cis-acting elements regulating transcription of the human DF3 breast carcinoma-associated antigen (N4UCI) gene,”Proc. Natl. Sci.,90:282-286 (1993).
Advani et al., “Radiogenatic therapy: on the interaction of viral therapy and ionizing radiation for improving local control of tumors,”Seminars in Oncology,24:633-638 (1997).
Anderson, “Human gene therapy,”Nature,392:25-30 (1998).
Arnberg et al., “Fiber genes of adenoviruses with tropism for the eye and the genital tract,”Virol.,227:239-244 (1997).
Ausubel et al., Current Protocols in Molecular Biology Suppl. 30 Sec. 7.7.18, Table 7.7.1, eds. (1987).
Babiss et al., “Celular promoters incorporated into the adenovirus genome. Effect of viral DNA replication on endogenous and exogenous gene transcription,”J. Mol. Biol.,193:643-650 (1987).
Bailey et al., “Cell type specific regulation of expression from the Ad40 E1b promoter in recombinant Ad5/Ad40 viruses,”Virol.,202:695-706 (1994).
Bailey et al., “Enteric adenovirus type 40: expression of E1B proteins in vitro and in vivo ,”Virol.,193:631-641 (1993).
Behringer et al.,“Dwarf mice produced by genetic ablation of growth hormone-expressing cells,”Genes Dev.,2:453-461 (1988).
Berkner et al., “Generation of adenovirus by transfection of plasmids,”Nuc. Acid Res.,11:6003-6020 (1983).
Bett et al., “An efficient and flexible system for construction of adenovirus vectors with insertions or deletions in early regions 1 and 3,”Proc. Nail. A cad. Sci.,91:8802-8806 (1994).
Bett et al., “Packaging capacity and stability of human adenovirus type 5 vectors,”Journal of Virology,67:5911-5921 (1993).
Bett et al., “Packaging capacity and stability of human adenovirus type 5 vectors,”J. Virol.,67:5911-5921 (1993).
Bridge et al., “Redundant control of adenovirus late gene expression by early region 4,”J. Virol.,63:631-638 (1989).
Bunn et al., “Oxygen sensing and molecular adaptation to hypoxia,”Physiol. Rev.,76:839-885 (1996).
Cannio et al., “A cell-type specific and enhancer-dependent silencer in the regulation of the expression of the human urokinase plasminogen activator gene,”Nuc. Acids Res.,19:2303-2308 (1991).
Coiditz, “Epidemiology of breast cancer. Findings from the nurses' health study,”Cancer,71:1480-1489 (1993).
Cuevas et al., “Specific oncolytic effect of a new hypoxia-inducible factor-dependent replicative adenovirus on von Hippel-Lindau-defective renal cell carcinomas,”Cancer Res,63:6877-6884 (2003).
Curiel, “Strategies to adapt adenoviral vectors for targeted delivery,”Ann NY Acad Sci.,886:158-171 (1999).
Dachs et al., “Targeting gene therapy to cancer: a review,”Oncolog Research,9:313-325 (1997).
Dachs et al., “The molecular response of mammalian cells to hypoxia and the potential for exploitation in cancer therapy,”Br. J. Cancer,74:S126-132 (1996).
Dachs et al., “Targeting gene expression to hypoxic tumor cells,”Nat. Med.,3:515-520 (1997).
Eck et al., “Gene-Based Therapy,” Chapter 5, Goodman & Gilman's The Pharmacological Basis of Therapeutics-Ninth Edition, McGraw-Hill: 77-101 (1996).
Feigner et al. “Cationic liposome-mediated transfection,”Nature,337:387-388 (1989).
Firth et al,, “Oxygen-Related Control Elements in the Phosphoglycerate Kinase 1 and Lactate Dehydrogenase A Genes: Similarities with the Erythropoietin 3′ Enhancer,”Proc. Nat. Acad. Sci.,91: 6496-6500 (1994).
Flint, “Expression of adenoviral genetic information in productively infected cells,”Biochem. Biophys. Acta,651:175-208 (1982).
Flint, “Regulation of adenovirus mRNA formation,”Adv. Vir. Res.,31:169-228 (1986).
Folkman, “What is the evidence that tumors are angiogenesis dependent?”Natl. Cancer Inst.,82:4-6 (1990).
Frankel et al., “Selection and characterization of ricin toxin A-chain mutations inSaccharomyces cerevisiae,” Mol. Cell. Biol.,9:415-420 (1989).
Graham, “Covalently closed circles of human adenovirus DNA are infectious,”EMBO J.,3:2917-2922 (1984).
Grand, “The structure and functions of the adenovirus early region 1 proteins,”Biochern. J.,241: 25-38 (1987).
Grooteclaes et al., “The 6-kilobase c-erbB2 promoter contains positive and negative regulatory elements functional in human mammary cell lines,”Cancer Res.,54:4193-4199 (1994).
Guillemin et al., “The hypoxic response: huffing and HIFing,”Cell,89:9-12 (1997).
Hallahan et al., “Spatial and temporal control of gene therapy using ionizing radiation,”Nat. Med.,1:786-791 (1995).
Hernandez-Alcoceba et al., “New oncolytic adenoviruses with hypoxia—and estrogen receptor-regulated replication,”Human Gene Therapy,13:1737-1750 (2002).
Hobbs et al., “Regulation of transport pathways in tumor vessels: Role of tumor type and microenvironment,”Proc. Natl. Acad. Sci.,95:4607-4612 (1998).
Hockel et al., “Hypoxia and Radiation Response in Human Tumors,”Semin. Rad. Oncol.,6:3-9 (1996).
Hudson et al., “Structure and inducible regulation of the human c-erb B2
eu promoter,”J. Biol. Chem.,265:4389-4393 (1990).
Ido et al., “Gene therapy for hepatoma cells using a retrovirus vector carrying herpes simplex virus thymidine kinase gene under the control of human alpha-fetoprotein gene promoter,”Cancer Res.,55:3105-3109 (1995).
Ishii et al., “Characterization of the promoter region of the human c-erbB-2 protooncogene,”Proc. Natl. Acad. Sci.,84:4374-4378 (1987).
Jain, “Delivery of molecular and cellular medicine to solid tumors,”J. Controlled Release,53:49-67 (1997).
Jiang et al., “V-SRC induces expression of hypoxia-inducible factor 1 (HIF-1) and transcription of genes encoding vascular endothelial growth factor and enolase 1: involvement of HIF-1 in tumor progression,”Can. Res.,57:5328-5335 (1997).
Johnson et al., “Autoregulatory control of E2F1 expression in response to positive and neg
Henderson Daniel R.
Yu De Chao
Cold Genesys, Inc.
Schultz James (Doug)
Stetina Brunda Garred & Brucker
LandOfFree
Adenovirus vectors containing cell status-specific response... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Adenovirus vectors containing cell status-specific response..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Adenovirus vectors containing cell status-specific response... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2643022